Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Antibodies Studied

  • 3 Antibodies
HMS LINCS ID Name Alternative Names Clone Name LINCS ID Resource Identification Initiative ID Nominal Protein Target HMS LINCS ID(s)
80076-1
Trastuzumab
Herceptin; rhuMAb HER2
huMAb4D5-8
80077-1
Pertuzumab
Omnitag; Perjeta
rhuMAb2C4
80078-1
Cetuximab
Erbitux
  • 3 Antibodies